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The Cellular Localization of Human Cytomegalovirus
Glycoprotein Expression Greatly Influences the Frequency
and Functional Phenotype of Specific CD4+ T Cell Responses
Annette Pachnio,* Jianmin Zuo,* Gordon B. Ryan,* Jusnara Begum,* and
Paul A. H. Moss*,†
CMV infection is a significant cause of morbidity and mortality in immunocompromised individuals, and the development of a vac-
cine is of high priority. Glycoprotein B (gB) is a leading vaccine candidate but the glycoprotein H (gH) pentameric complex is now
recognized as the major target for neutralizing Abs. However, little is known about the T cell immune response against gH and
glycoprotein L (gL) and this is likely to be an important attribute for vaccine immunogenicity. In this study, we examine and contrast
the magnitude and phenotype of the T cell immune response against gB, gH, and gL within healthy donors. gB-specific CD4+ T cells
were found in 95% of donors, and 29 epitopes were defined with gB-specific response sizes ranging from 0.02 to 2.88% of the CD4+
T cell pool. In contrast, only 20% of donors exhibited a T cell response against gH or gL. Additionally, gB-specific CD4+ T cells
exhibited a more cytotoxic phenotype, with high levels of granzyme B expression. Glycoproteins were effectively presented
following delivery to APCs but only gB-derived epitopes were presented following endogenous synthesis. gB expression was
observed exclusively within vesicular structures colocalizing with HLA-DM whereas gH was distributed evenly throughout the
cytoplasm. Grafting of the C-terminal domain from gB onto gH could not transfer this pattern of presentation. These results
reveal that gB is a uniquely immunogenic CMV glycoprotein and this is likely to reflect its unique pattern of endogenous Ag
presentation. Consideration may be required toward mechanisms that boost cellular immunity to gH and gL within future subunit
vaccines. The Journal of Immunology, 2015, 195: 3803–3815.
C
ytomegalovirus can cause severe disease in the setting of
congenital infection or immune suppression, and devel-
opment of a CMV vaccine has been given high priority
by the Institute of Medicine (1–6). Such a vaccine would have
two main aims: first, the induction of neutralizing Abs to prevent
vertical transmission as a means to prevent congenital CMV in-
fection; second, the induction or boosting of T cell immunity in
individuals that already carry the virus may improve the virus–
host balance within patients such as those receiving solid organ or
stem cell transplants. This latter ambition is supported by sub-
stantial evidence underpinning the role of virus-specific T cells in
controlling viral replication, especially in the setting of allogeneic
transplantation (7–11). A particular role for CD4+ T cells has also
been shown in reducing viral transmission at time of primary in-
fection during pregnancy (12).
The principal target protein to date, and the most advanced in
terms of vaccine development, has been glycoprotein B (gB), one
of the most abundant proteins within the viral envelope and im-
portant for viral entry (13, 14). Abs against gB can prevent viral
infection of fibroblast target cells (15, 16), and a number of vac-
cines have been developed, including adjuvanted gB protein, DNA
vaccines encoding gB and pp65, and alphavirus replicon particles
expressing gB, pp65, and IE-1 (17–20). Initial studies demon-
strated a 50% efficacy in protecting women against primary in-
fection and a reduction in the duration of viremia and requirement
for antiviral treatment following solid organ transplantation in
CMV-seronegative recipients. However, recent results from mul-
ticenter studies suggest somewhat less efficacy in relation to
prevention of primary infection (21), and there is a considerable
need to improve the efficacy of next-generation vaccines. Impor-
tantly, recent investigations have shown that the gH pentameric
complex, containing glycoprotein H (gH), glycoprotein L (gL),
UL128, UL130, and UL131A, is essential for viral entry into
epithelial and endothelial cells (22), which represent principal
target cells of CMV infection in vivo. Furthermore, most neu-
tralizing Abs are directed against this complex rather than gB (23–
25), and current CMV vaccines largely fail to induce epithelial
entry-specific neutralizing Abs to levels seen in healthy donors
(26). As a consequence, the focus of vaccine development has now
shifted to include components of the pentameric complex, such as
gH and gL, which as a heterodimer gH/gL in conjunction with gB
are essential for viral entry into the cell. These proteins play im-
portant roles in viral cell attachment, cell-to-cell spread, and fusion
with the cell membrane. Indeed, lack of any one of these compo-
nents abrogates initiation of the fusion process (27, 28), and studies
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in a guinea pig model have demonstrated the ability of an Ab directed
against gH/gL to protect against congenital CMV infection (29).
Recent progress, however, suggests that protection against
CMV-related disease requires both humoral and cellular immu-
nity. Therefore, the ability to induce both has been recognized as an
important attribute for an optimal vaccine candidate (30). Screening
of the viral proteome identified gB as the most immunodominant
CD4 T cell target from 213 CMV open reading frames (31). This
study did not investigate individual peptide epitopes although
a limited number of epitopes have now been described. Whereas
CD8+ T cell epitopes have also been identified, most are re-
stricted through HLA class II alleles (32–36). Of these, the HLA
DRB1*0701 (DR7)–restricted peptide epitope DYSNTHSTRYV
(DYS) is of particular interest, as it induces arguably the largest
CD4+ T cell response observed against a pathogen to date (37). Up
to 16% of the total CD4+ T cell pool can be directed against this
single viral epitope, and the TCR usage for this particular epitope
is highly conserved between individuals (38). Furthermore, fol-
lowing endogenous synthesis gB epitopes are presented efficiently
at the cell surface within HLA class II. This efficient access into
the MHC class II pathway stems from a sorting sequence in the
C-terminal region of gB that directs it into the endosomal com-
partment of the cell, therefore providing direct access to the HLA
class II Ag-processing pathway (39). This targeting may explain
the immunodominance of this glycoprotein, as it allows direct
presentation of the Ag for CD4+ T cell recognition by infected
cells without the need for cross-presentation by professional
APCs. Despite these findings, detailed studies about individual
gB-derived epitopes are missing. Moreover, very little is known
about the cellular immune response against the other two major
CMV glycoproteins, gH and gL (37, 40) although it has been
suggested that these proteins may also represent good CD4+ T cell
targets as, such as gB, they localize to the trans-Golgi network
(TGN)/endosomal compartment, which acts as the site of virus
assembly in infected cells. As such, gH and gL protein could have
relatively easy access to the HLA class II pathway.
In this study, we have undertaken a comprehensive analysis of
the T cell immune response to three major CMV-derived glyco-
proteins, gB, gH, and gL. The aim was to determine the relative
immunodominance of the glycoproteins, identify novel epitopes
within each protein, and investigate potential mechanisms that
might underlie this pattern. This work is very important in relation
to design of the appropriate components within a future CMV
vaccine formulation. Our results reveal a remarkable difference in
the cellular immunodominance of gB in comparison with gH and
gL, which correlates with the pattern of cellular localization and
ability to undergo direct endogenous presentation to CD4+ T cells.
Moreover, the data suggest that subunit components of gH and gL
may represent poor components for a CMV vaccine unless ap-
proaches such as protein conjugation are undertaken to provide
T cell help to support generation of high-affinity humoral immunity.
Materials and Methods
Subjects
Seventeen healthy CMV-seropositive donors and one CMV-seronegative
donor were recruited into the study. Supplemental Table I contains infor-
mation about donor age and HLA class II genotype. Ethical permission
was granted by the West Midlands (Black Country) Research Ethics
Committee (REC 07/Q2702/24), and all donors gave written informed
consent.
Peptide libraries of CMV-derived glycoproteins
To screen for T cell responses specific for three CMV glycoproteins gB, gH,
and gL, peptide libraries were purchased from Alta Biosciences. Each li-
brary consisted of sequential peptides 20 aa in length, overlapping by 15 aa
and spanning the whole sequence of the protein. For gB (GenBank/Swiss-
Prot ID CAA35414) the library comprised 179 peptides, for gH (GenBank
ID CAA35390.1) 146 peptides were synthesized, and the gL (UniProtKB/
Swiss-Prot ID P16832.2) library contained 53 peptides. All individual
peptides were dissolved in DMSO and peptide pools were generated for
each glycoprotein based on a screening cross-matrix designed as previously
described (41). One example for this approach can be found in Supplemental
Fig. 1. By doing this, each peptide was contained exactly within two pools,
which allowed rapid identification of immunogenic peptide epitopes.
Isolation and stimulation of PBMCs
Heparinized blood (60 ml) was collected and lymphocytes were isolated by
density gradient centrifugation using Lympholyte cell separation media
(Cedarlane). To identify virus-specific T cells within the PBMC fraction, 1.53
106 freshly isolated cells were resupended in 500 ml RPMI 1640 supple-
mented with 10% FCS and 1% penicillin/streptomycin. Peptides were
added at a final concentration of 5 mg/ml and PBMCs were then incubated
overnight at 37˚C and 5% CO2 in the presence of brefeldin A (10 mg/ml
final concentration; Sigma-Aldrich) to block cytokine secretion. Cells stimu-
lated with an equivalent volume of DMSO served as a negative control;
PBMCs stimulated with staphylococcal enterotoxin B (final concentration,
0.2 mg/ml; Sigma-Aldrich) functioned as a positive control.
Intracellular cytokine staining
Following overnight stimulation, activated T cells were identified by flow
cytometric detection of intracellular IFN-g expression. For this, cells were
washed with 13 PBS and stained with Live/Dead fixable violet stain
(Invitrogen) for 15 min at room temperature (RT) followed by one wash in
13 PBS and one in staining buffer (13 PBS plus 0.5% BSA and 2 mM
EDTA). T cells were then identified by staining with anti–CD4-PE (BD
Biosciences) and anti–CD8-PECy5 (Beckman Coulter), and B cells were
excluded by staining with anti-CD19 Pacific Blue (eBioscience; dump
channel). Cells were incubated for 15 min at 4˚C before washing off excess
Ab with staining buffer. Fixing was carried out with 4% paraformaldehyde
(in PBS; Sigma-Aldrich) for 15 min at RT before permeabilizing with
0.5% saponin (in PBS; Sigma-Aldrich) for 5 min. Intracellular IFN-g was
then stained with an anti–IFN-g FITC Ab (BD Biosciences) followed by
a final wash in staining buffer. Acquisition was carried out on an LSR II
flow cytometer and FACSDiva software (BD Biosciences) collecting
300,000 live lymphocytes, and data were analyzed using FlowJo software
version 7.6.5 (Tree Star). For the analysis, doublets were excluded based
on forward scatter height versus forward scatter area, followed by exclu-
sion of dead cells and CD19+ cells. The lymphocyte population was then
gated on a forward scatter area versus side scatter area scatter plot (see
Fig. 1B), and the proportion of IFN-g–producing cells was determined
within the CD4 or CD8 T cell subset. A cytokine response was defined as
positive when the frequency of cytokine-producing cells was at least 2-fold
increased above background frequency detected in the corresponding DMSO-
stimulated sample.
For the extended functional analysis of glycoprotein-specific T cells,
PBMCs were stimulated as described above, stained with Live/Dead fix-
able violet stain (Invitrogen), followed by surface staining with anti-CD19
(to exclude B cells; eBioscience), anti–CD3-AmCyan, and anti–CD4-PE-
CF594 (both BD Biosciences). Following fixation and permeabilization,
cells were then stained for intracellular IFN-g FITC (BD Biosciences),
TNF-a PE-Cy7 (eBioscience), IL-2 PE (BioLegend), and a marker for
cytotoxic potential granzyme B (GzmB) Alexa Fluor 647 (BioLegend).
Acquisition was carried out as above. Analysis was done using FlowJo
version 7.6.5 and SPICE version 5.3 (42). For analysis, single, live, CD192
lymphocytes were gated. Of these, CD3+ cells were identified and CD4+
T cells were gated on. Using Boolean gating, all combinations of responding
cells were determined using IFN-g, TNF-a, IL-2, and GzmB as read-out
parameters and background (DMSO control) was substracted.
T cell cloning
Once peptide epitopes were identified, a selection of CMV-specific CD4+
T cells were cloned to identify HLA restriction and to be used in further
experiments. PBMCs were isolated as above and CD8+ T cells depleted
using magnetic bead selection (Dynal) according to the manufacturer’s
instructions. Epitope-specific T cells were enriched with an IFN-g secre-
tion assay cell enrichment and detection kit (Miltenyi Biotec) following
a 3-h peptide stimulation. This was done according to the manufacturer’s
recommendations. Selected IFN-g–producing cells were then cloned by
limiting dilution in RPMI 1640 plus 5% human serum plus 1% penicillin/
streptomycin and seeded with PHA-treated, gamma-irradiated buffy cells
as well as peptide-loaded, gamma-irradiated autologous lymphoblastoid















cell lines (LCLs). After 3 d, cultures were fed with RPMI 1640 containing
60% MLA144 supernatant, 5% human serum, 1% penicillin/streptomycin,
and 100 U IL-2. Ag specificity of expanding cells was confirmed at ∼14 d.
For this either 5 3 104 peptide-loaded or DMSO-pulsed autologous LCLs
were cocultured overnight with expanded T cells, and IFN-g was detected
in the supernatant by ELISA as described below. For further expansion,
cells were cultured in RPMI 1640 containing 30% MLA144 supernatant,
10% FCS, 1% human serum, 1% penicillin/streptomycin, and 50 U IL-2
and occasionally restimulated with peptide-loaded, gamma-irradiated LCLs,
and gamma-irradiated feeder cells were added at the same time.
IFN-g ELISA
To detect activation of virus-specific T cells, these were cocultured with
Ag-loaded cells (fibroblasts or LCLs) and supernatants were analyzed for
secreted IFN-g using an ELISA (Thermo Scientific). Briefly, plates were
coated overnight with anti–IFN-g Ab followed by a blocking step with 1%
BSA in 13 PBS and 0.05% Tween 20. Culture supernatants were then
added to the plate and incubated for 2 h at RT followed by a wash step with
PBS–Tween 20. Bound IFN-g was detected with a secondary biotinylated
Ab for 1 h at RT, followed by a wash step and addition of ExtrAvidin-
peroxidase (Sigma-Aldrich). Substrate solution was added, the colori-
metric reaction stopped with 1 M HCl, and absorbance was measured at
450 nm.
HLA restriction analysis of T cell responses
To identify the HLA restriction of newly identified T cell epitopes, 2000
clonal T cells were cocultured overnight at 37˚C and 5% CO2 in V-bottom
plates with 5 3 104 peptide-loaded LCLs, which were either autologous
or partially HLA matched. DMSO-pulsed LCLs and T cells alone served
as controls. In some cases peptide-loaded LCLs were preincubated with
anti–HLA-DR or anti–HLA-DQ Abs for 2 h at 37˚C and 5% CO2 before
addition of the T cells. T cell activation was determined by detection of
IFN-g in the culture supernatant using ELISA as described above.
T cell recognition of virus-infected cells
Fibroblasts expressing the restricting HLA allele were seeded at 1.5 3 104
cells per well in a 96-well plate and treated with IFN-g for 72 h to induce
HLA class II expression. Cells were then infected at a multiplicity of in-
fection of 1 with a purified preparation of live CMV or UV-inactivated
virus (Merlin wild-type [WT] strain) and left for 24 h, then washed with
PBS before addition of 20,000 T cells. Peptide-loaded fibroblasts served as
a positive control, and uninfected fibroblasts and T cells alone served as
negative control. After overnight incubation at 37˚C and 5% CO2 super-
natants were analyzed for IFN-g production by ELISA (see above).
HLA-matched fibroblasts were not available for both epitopes, and
autologous PBMCs therefore served as target cells. PBMCs (only mono-
cytes are permissive for the virus) were infected with CMVat a multiplicity
of infection of 1 for 24 h, then washed with PBS and 13 105 infected cells
were cocultured with 5000 T cells in a 96-well V-bottom plate. Uninfected
PBMCs served as a negative control. IFN-g was detected in the superna-
tant following 18 h of coculture at 37˚C and 5% CO2 using ELISA.
Plasmids and transfection
To express the gB-V5 and gH-V5 proteins, the human CMV (HCMV) gB
(UL55) and gH (UL75) genes were subcloned into the pcDNA3.1-V5
plasmid vector. For the expression of GFP fusion protein, the HCMV gB
and gH genes were then sublconed into pd2EGFP-N1 vector, in which the
GFP is fused to the C terminus of the glycoprotein. All constructs were
verified by restriction digest and sequence analysis. Transient transfection of
human embryonic kidney (HEK)293 cells (American Type Culture Collection)
and MelJuSo (MJS) cells (a human melanoma–derived cell line) (43) with
plasmid DNAwas routinely performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.
Western blot analysis of protein expression
To confirm that proteins were expressed, HEK293 cells were transiently
transfected with the glycoprotein constructs using Lipofectamin 2000
according to the manufacturer’s recommendations. Twenty-four hours later
cells were harvested and lysates generated by sonication. Proteins of a 20-
ml sample were separated by SDS-PAGE using Novex 4–12% Bis-Tris gels
and MOPS running buffer (Invitrogen) and then transferred onto a poly-
vinylidene difluoride membrane (Invitrogen) by electroblotting. Following
a blocking step (5% milk in PBS–Tween 20) CMV glycoproteins were
detected by an anti-V5 Ab (primary Ab; Invitrogen) and an anti-mouse
peroxidase-conjugated secondary Ab (Sigma-Aldrich). Detection was done
using an ECL detection kit (GE Healthcare) following the manufacturer’s
instructions for developing and a ChemiDoc MP imaging system (Bio-
Rad). ImageLab software was used to quantify expression levels of the
proteins analyzed.
T cell recognition of Ag taken up exogenously
After quantification as described above, equal amounts of each glycoprotein
were fed to autologous LCL overnight in Opti-MEMmedia at 37˚C and 5%
CO2. Excess lysate was washed off and 1 3 10
5 LCLs were cocultured
with 5000 clonal T cells overnight in RPMI 1640 plus 10% FCS and
penicillin/streptomycin before IFN-g content was determined in the culture
supernatant by ELISA (as above).
T cell recognition of endogenously processed Ag
Autologous LCLs were transfected by electroporation (settings at 270 Vand
950 mF) in Opti-MEM media, then transferred into RPMI 1640 plus 10%
FCS and penicillin/streptomycin for 24 h. Dead cells were removed by
density gradient centrifugation with Lympholyte cell separation media
(Cedarlane) before use in the assay. To analyze T cell recognition, 5000
clonal T cells were cocultured overnight in V-bottom plates with 1 3 105
transfected LCLs at 37˚C and 5% CO2. Supernatants were harvested and
analyzed for IFN-g by ELISA as described above.
Confocal microscopy
MJS cells were seeded onto coverslips and transiently transfected with
GFP-expressing constructs the following day using Lipofectamine 2000
according to the manufacturer’s recommendations. Twenty-four hours later
cells were fixed and permeabilized with methanol/acetone (1:1) for 20 min
at 220˚C. Following a blocking step, costaining with a mouse anti–HLA-
DMa Ab (Abcam) for 2 h at RTwas carried out. Subsequently, slides were
washed with 13 PBS before addition of an anti-mouse IgG1 Alexa Fluor
594 Ab for 1 h at RT. Following another wash step with 13 PBS, cov-
erslips were mounted onto microscope slides with DAPI containing Vec-
tashield mounting media (Vector Laboratories) and sealed. Analysis was
done on a laser scanning microscope (LSM) 510 confocal microscope and
LSM image browser (Zeiss).
Results
gB induces strong CD4+ T cell responses against a wide range
of peptide epitopes
gB is an immunodominant CD4+ T cell target (31) but only a
limited number of HLA class II–restricted T cell epitopes have been
identified from within the protein, and cellular immunity against
other glycoproteins has not been investigated in detail. We chose to
investigate T cell immune responses against gH and gL, as these
glycoproteins are abundant within the viral envelope and form
a major component of the pentameric complex, which is currently
a focus of vaccine development.
gB is a type I transmembrane protein, 906 aa in length, and
contains a furin cleavage site at position 459 and a long cytoplasmic
domain of 136 aa (Fig. 1A). gH is also a type I transmembrane
protein and at 743 aa in length it is 82% of the length of gB with
a C-terminal domain of only 7 aa. gL is much smaller at 278 aa,
30% the size of gB, and is anchored in the viral envelope by its
close association to gH but itself lacks a transmembrane domain.
Peptide pools of each protein were designed using a cross-matrix
such that each peptide was contained in exactly two of the pools
(41). This approach allows rapid identification of antigenic pep-
tides. As an example, the gB pools 14–27 contained overlapping
peptides consecutively spanning the whole sequence of the pro-
tein, whereas pools 1–13 were made up of every 13th peptide in
the sequence (Supplemental Fig. 1). In the same fashion, peptide
pools were generated for both gH and gL, with the former
screening matrix consisting of 25 pools and the latter of 15 pools.
Peptide-specific T cells were identified by flow cytometric anal-
ysis of intracellular cytokine production following stimulation of
PBMCs with the peptide pools (intracellular cytokine staining
[ICS]). IFN-g was used for analysis, as the vast majority of CMV-
specific T cells have been shown to produce this cytokine in re-















sponse to Ag stimulus (44). ICS allowed simultaneous detection of
CD4+ and CD8+ T cells and was highly sensitive. In particular,
T cell responses as low as 0.008% of the T cell subset were readily
identifiable using this approach, and experimental criteria are
described in Materials and Methods. Fig. 1B shows a representa-
tive example of CD4+ T cell responses detected in one donor,
ranging from 0.02 to 2.19% of all CD4+ T cells induced by one
pool of peptides used to stimulate the PBMCs. In cases where an
immune response was detected against an individual peptide pool,
PBMCs were subsequently stimulated with individual peptides
from the pool to identify specific epitope responses (Fig. 1B).
PBMCs from 17 CMV-seropositive donors were screened for
T cell reactivity against gB (Supplemental Table I). gB-specific
CD4+ T cells were identified in all but one of the donors (Fig. 2A).
No responses were observed in CMV-seronegative donors. Peptide
epitopes were derived from along the majority of the protein se-
quence, but interestingly they were not detectable from the first
80 aa (pool 14) or the transmembrane domain (contained in pool
25). Each donor responded to at least two peptide epitopes, with
a maximal response to five peptides in donor 3. The vast majority
of these T cell responses were restricted through CD4, but also
two CD8-restricted T cell responses were identified (donors 5 and
8). In the subscreening, generally one to three consecutive pep-
tides were able to elicit T cell reactivity. Of those, the single
peptide capable of inducing the largest IFN-g response was de-
fined as the peptide epitope (Fig. 1B), although minimal peptide
epitopes have not been further characterized so far. Using this ap-
proach, 29 individual peptides were identified to contain CD4+
T cell epitopes, of which only 5 have previously been reported
(Supplemental Table II). Just two CD8-restricted T cell epitopes
were identified, both of which have not been previously known
(Supplemental Table II). The magnitude of the gB-specific CD4+
T cell response ranged from 0.06 to 2.88% of the total CD4+ T cell
population, with a maximal response of 1.8% against one single
epitope (Fig. 2B). Unsurprisingly, DYS was not the only epitope
capable of inducing such a large T cell response. In 9 of 17 donors,
.0.3% of all CD4+ T cells were specific for one single epitope, and
in most cases this was not the only epitope per donor. A median of
1.22% (range, 0.34–2.88%) of all CD4+ T cells were directed
against gB in those individuals. Apart from one HLA-DR7+ donor,
the T cell response to the known HLA-DR7–restricted epitope DYS
was the largest one observed in these individuals, but it did not
always reach the extremes previously observed in elderly donors
(38). In the remaining seven donors, ,0.15% of CD4+ T cells were
specific for one single epitope, but most displayed T cells specific
for more than one single epitope (between one and four) with
a median response size of 0.17% (range, 0.05–0.25%) of all CD4+
T cells. This was independent of the donor age.
gH and gL contain far fewer T cell epitopes than does gB
It has been speculated that, similar to gB, the other CMV glyco-
proteins would also represent very good targets for CD4+ T cells,
FIGURE 1. Identification of peptide-
specific T cells by intracellular cytokine
staining for IFN-g. (A) Schematic repre-
sentation of the three CMV-derived glyco-
proteins studied. The identification of
a CD4-restricted gB-derived epitope is
shown as an example in (B). PBMCs were
stimulated overnight, then stained with
Live/Dead fixable violet stain and anti-
CD19 (dump channel) as well as anti-CD4
and anti-CD8. After fixation (4% parafor-
maldehyde) and permeabilization with
0.5% saponin, activated T cells were
identified by staining with anti–IFN-g.
DMSO and staphylococcal enterotoxin B
(SEB)–stimulated cells served as negative
or positive controls, respectively. Shown
are the gating strategy (top row) and results
of the first round of screening (middle row).
The individual peptide epitope was then
identified in a subsequent screening (bot-
tom row). Numbers indicate the frequency
of IFN-g–producing cells within the total
CD4+ T cell population. FSC-A, forward
scatter area; FSC-H, forward scatter height;
SSC-A, side scatter area.















based on the fact that the TGN is the site of virus assembly in
infected cells (45). Therefore, we undertook a detailed analysis of
the T cell response to gH and gL, as these are the two other
conserved major glycoproteins contained in the viral envelope and
the pentameric complex.
Using the same peptide cross-matrix approach, 15 of the 17
donors screened for gB responses were tested for responses against
gH and gL using ICS. In contrast to gB, gH-specific CD4+ T cells
were only detected in three donors and no CD8+ T cell responses
were observed (Fig. 2C). The magnitude of these responses ranged
from 0.008 to 1.14% of the total CD4+ T cell population (median,
0.24%). The frequency of T cell responses against gL was com-
parable in that responses were again observed in only three donors
(Fig. 2C). Two of these were CD4-restricted T cell epitopes (0.02–
0.03% of CD4+ T cells), whereas the third was restricted through
CD8 (0.014% of total CD8+ population). Interestingly, although
far fewer T cell epitopes are contained within the gH and gL
proteins, the magnitude of those responses identified was com-
parable to those against gB. Indeed, when the magnitude of the
T cell response against gB is compared with that directed against
gH or gL, respectively, no significant difference was observed in
the median response size (Fig. 2D). The peptides identified to
contain T cell epitopes, and the magnitude of the T cell response,
are both summarized in Supplemental Table II.
gB-specific T cells display a distinct pattern of polyfunctional
capacity following antigenic stimulation
In addition to examining the magnitude of the T cell response
against gB, gH, and gL, we next examined the functional profile of
CD4+ T cell responses against the three glycoproteins in more
detail. The individual and combinatorial patterns of IFN-g, TNF-a,
IL-2, and GzmB expression was determined to assess the poly-
functional profile of the virus-specific cells. This analysis was
performed for T cells recognizing newly identified gB-derived
epitopes (n = 7) and also for those specific for all epitopes iden-
tified within gH (n = 7) and gL (n = 2).
FIGURE 2. T cell responses are much more frequent against gB than against gH and gL. Summary of gB screening results (A). With the exception of one
donor, T cells producing IFN-g in response to stimulation with peptides derived from gB could be detected in all CMV-seropositive subjects tested. Peptide
epitopes can be found along most of the protein sequence, consecutively contained in pools 14–27. The T cell response to gB varies greatly in magnitude
and number of epitopes recognized (B). The proportion of CD4+ T cells responding to individual gB-derived epitopes is shown for each donor. Up to six
peptide epitopes were identified per donor. DYS-specific responses, which have been previously reported, are highlighted in red. In comparison, T cell
responses to gH and gL are much less frequent as summarized in (C). The response magnitudes were comparable to those against gB (D). Individual T cell
responses are shown as a proportion of total CD4+ T cells for each of the glycoproteins studied. Each bar represents the median CD4+ T cell response size
with interquartile range.















gB-specific CD4+ T cells displayed a strongly cytotoxic phe-
notype (87% GzmB+) following peptide stimulation with very
high levels of TNF-a and IFN-g production (Fig. 3). Only 26% of
responding cells expressed IL-2, although 16% exhibited a com-
plete polyfunctional profile by expression of all four markers. In
contrast, gH-specific T cells exhibited a markedly reduced cyto-
toxic profile, with GzmB expression observed in only 26% of
cells, although it was noteworthy that 59% of gH-specific T cells
retain the capacity to produce IL-2. T cell responses against the
two gL-derived epitopes were comparable to those seen for gH-
specific T cells (Fig. 3, bar charts).
Glycoprotein-specific CD4+ T cells display a broad range of
HLA restrictions and have moderate affinity for Ag
To investigate why other glycoproteins besides gB were poor CD4
T cell targets, we prepared CD4+ T cell clones specific for rep-
resentative epitopes in all three proteins. Using IFN-g capture
enrichment and cloning by limiting dilution, T cell clones specific
for five epitopes derived from gB and one each from gH and
gL were generated. The isolation of CD4+ T cell clones allowed
determination of the HLA restriction of these new epitopes, as-
sessment of functional avidity of the T cell clones, and investi-
gation of whether and when the epitopes are generated during
the course of natural infection. Subsequently, the epitopes are
named using the first three amino acids of the respective pep-
tide sequence.
Table I lists the protein, peptide sequence, and HLA restriction
of all seven cloned T cell responses. The HLA restriction of each
clone was determined with the use of LCLs. Clones were tested
for recognition of peptide-loaded autologous LCLs and also al-
logeneic, peptide-loaded LCLs that were partially matched for
specific HLA class II alleles. Three examples from this analysis
are shown in Fig. 4A. The HLA restriction of both the gB-
derived epitope IRS and gH-derived epitope QLN was defined
with T cell clones from donor 9, and gL-derived epitope T cell
clones were generated from donor 11. Peptide IRS was presented
only by LCLs sharing HLA-DR7, thus identifying this as the
restricting allele. The QLN response was analyzed in the same
donor using the same panel of partially matched LCLs. T cell
recognition was blocked completely by preincubation with an
anti–HLA-DR Ab, however none of the allogeneic LCLs induced
T cell recognition. As the DR7 restriction of IRS-specific clones
from the same individual was clearly identified using this panel
of LCLs, we concluded that this epitope is HLA-DR4 restricted.
Several subtypes of HLA-DR4 have been observed, and poly-
morphisms occur in regions of the molecule that play a role in
the interaction of the TCR and its Ag (46, 47). This may explain
why this particular epitope was only presented by autologous
LCLs. HLA-DR4 and -DR7 are both extremely closely linked to
DR53, but no such subtype-specific differences have been re-
ported for this HLA allele, supporting our conclusion that the
QLN epitope is HLA-DR4 restricted. The final example shows
the HLA restriction of the gL-derived epitope QGD, which was
determined to be HLA-DP8.
The functional avidity of T cell clones specific for the three
peptide epitopes was determined by peptide titration analysis
(Fig. 4B). Autologous LCLs were loaded with decreasing con-
centrations of the epitope peptide, and functional avidity was
defined as that peptide concentration that induced a half-maximal
IFN-g response. This value was very similar for IRS- and QLN-
specific T cell clones, with ∼300 nM. The QGD-specific T cell
clones displayed a slightly higher avidity of ∼50 nM. These
values are comparable to values of other virus-specific CD4+
T cells (48, 49).
Glycoprotein-specific T cell clones recognize CMV-infected
target cells and do not require de novo protein synthesis
Another major incentive for generating T cell clones was to use
these to confirm that the individual peptide epitopes were presented
during the course of natural viral infection of a target cell. In case of
the DR7-restriced epitope IRS, HLA-matched fibroblasts were
treated with IFN-g to induce HLA class II expression and then
FIGURE 3. Glycoprotein-specific
T cells vary in their functional
capacities. Functional characteriza-
tion of glycoprotein-specific T cells
was carried out following peptide
stimulation of PBMCs using multi-
color flow cytometric analysis, and
a Boolean gating strategy was ap-
plied. Bar charts represent individual
data for responses against each of the
three glycoproteins studied. Shown
are box-and-whisker plots represent-
ing median values with interqartile
range and minimum and maximum
values. Pie charts summarize the data
for gB and gH and represent the
proportion of responding cells with
cytotoxic potential and/or single, dou-
ble, or triple cytokine production
capacity.















infected with a purified preparation of CMV (Merlin strain) for
24 h prior to addition of T cell clones. Recognition of the Ag was
determined by detection of IFN-g within the culture supernatant.
Peptide-loaded and uninfected fibroblasts served as controls.
Results show that T cells were indeed able to recognize virus-
infected fibroblasts (Fig. 5A). Furthermore, infection of fibro-
blasts with a UV-inactivated CMV preparation established that de
novo protein synthesis was not necessary, showing that incoming
virus particles contained sufficient amounts of gB to sensitize
specific T cells. For the gH-derived epitope QLN, no HLA-
matched fibroblasts were available and we therefore infected
autologous PBMCs with virus, as monocytes are permissive for
infection. This confirmed that the peptide epitope QLN was also
generated efficiently in the context of a viral infection (Fig. 5B).
Peptide epitopes from gH are not presented following
endogenous protein synthesis, and this is not overcome by
addition of the C-terminal domain from gB
Because the first part of the present study had revealed profound
differences between the immunogenicity of gB in relation to gH
and gL, we then went on to study Ag processing of CMV gly-
coproteins. gB and gH were chosen, as they are both transmem-
brane proteins and similar in size. T cell clones specific for
a gB-derived epitope (IRS) and a gH-derived epitope (QLN) were
generated from the same donor, and these were selected to in-
vestigate suspected differences in Ag processing of the two gly-
coproteins. Interestingly, peptide dilution analyses showed that the
avidity of these clones was very similar. The C-terminal domain
of gB has been suggested to contain a sorting sequence directing
it into the HLA class II processing pathway, leading directly
to endogenous processing for Ag presentation, and therefore
bypassing cross-presentation (39). This report also suggested that
other CMV glycoproteins might represent good CD4+ T cell tar-
gets, as the TGN/endosomal compartment of virus-infected cells
acts as the site of virus assembly. To address this question, we
generated four recombinant glycoprotein constructs to analyze the
importance of the potential sorting sequence contained within the
C-terminal domain of gB (Fig. 6A). Two of these expressed WT
gB (gB-WT) or gH (gH-WT), whereas the third contained a
deletion of the C-terminal domain of gB (gBDCT) and the final
vector adjoined this C terminus to WT gH (gH-gBCT). The
constructs contained either a C-terminal V5 tag or GFP to allow
detection of protein expression.
Initial experiments analyzed classical HLA class II Ag pre-
sentation through uptake of exogenous Ag by APCs via endocy-
tosis, followed by processing and presentation at the cell surface in
the context of HLA class II. HEK293 cells were transfected with
each of the four constructs, harvested after 24 h, and then sonicated
to generate cell lysate. Expression of the protein was confirmed by
Western blot analysis (Fig. 6B) and quantified by densitometry.
Equal amounts of protein were fed to autologous LCLs overnight
to allow uptake and processing of the Ag for presentation at the
cell surface. T cell recognition was then analyzed by detection of
Table I. Protein origin, peptide sequence, and HLA class II restriction
of newly identified CD4+ T cell epitopes








Epitopes are named using the first three amino acids of their peptide sequence, as
highlighted in bold.
FIGURE 4. HLA restriction and
functional avidity of CD4+ T cell
clones specific for gB, gH, and gL.
Representative examples of HLA re-
striction assays: clonal T cells were
cocultured with either autologous
or partially HLA-matched peptide-
loaded LCLs, and IFN-g was de-
tected in the supernatant to analyze
T cell activation (A). The functional
avidity of CD4+ T cell clones spe-
cific for the same epitopes was
investigated by preincubation of
autologous LCLs with decreasing
concentrations of the peptide, fol-
lowed by measurement of IFN-g
release after incubation with T cells
(B). Each experiment was carried
out at least twice in duplicates.















IFN-g in the supernatant following coculture of target cells with
epitope-specific T cell clones. For each epitope, two T cell clones
were tested in the assay. LCLs pulsed with lysate of untransfected
HEK293 cells and peptide-loaded LCLs served as controls. All
four proteins were found to be processed via the exogenous route
for Ag presentation with a clear IFN-g response to LCLs incu-
bated with HEK293 lysate expressing the relevant glycoprotein
(Fig. 6C), thus confirming that all four proteins can be processed
and presented in the classical way.
We then went on to investigate whether the epitopes could also
be generated from endogenous protein production and enter the
HLA class II Ag presentation pathway in a nonclassical manner.
Autologous LCLs were transfected with the individual constructs
using electroporation, and dead cells were removed after 24 h by
gradient centrifugation. Protein expression was confirmed by flow
cytometric detection of GFP+ cells, and cells were then cocultured
with T cell clones prior to detection of IFN-g release using
ELISA. As expected, the gB-derived epitope IRS was indeed
generated through an endogenous route of presentation with T cell
recognition observed from both T cell clones (Fig. 6D). In con-
trast, the QLN epitope from gH was not presented at the cell
surface following endogenous synthesis of the glycoprotein. In the
next step we examined the influence of deletion of the C-terminal
domain of gB on the efficiency of peptide presentation following
electroporation. Surprisingly, deletion of the domain had very
little effect on T cell recognition, with only a slight reduction in
IFN-g release following target cell transfection with the gBDCT
construct. Moreover, the addition of the gB C-terminal domain to
WT gH did not lead to processing and presentation of the QLN
epitope via an endogenous pathway.
gB and gH exhibit differential cellular localization
The studies above indicate that gB and gH undergo different
patterns of Ag processing during viral infection. An important
aspect of this will be their localization within the cell, but to date
this has only been investigated in detail for gB. We therefore
analyzed the cellular localization of both gB and gH, and also
studied whether exchange of the gB C-terminal domain between
the two proteins would modulate the observed pattern. GFP-
expressing constructs were used to visualize the cellular locali-
zation of proteins expressed from the gB, gH, gBDCT, and
gH-gBCT vectors.
MJS cells were transfected, fixed, and permeabilized after 24 h
using methanol/acetone (1:1). These were then counterstained with
DAPI and mounted on microscope slides for analysis on an LSM
510 confocal microscope. Glycoprotein B expression was con-
tained exclusively to vesicular structures throughout the cyto-
plasm of the cells (Supplemental Fig. 2, top left), in agreement
with previous studies. In contrast, gH was distributed evenly
within the cytoplasm and did not show any vesicular localization
(Supplemental Fig. 2, bottom left). Removal of the C-terminal
domain from gB (gBDCT) broadened expression of the protein
to include both vesicular and cytoplasmic distribution of the
protein. However, when this domain was added to gH, in the gH-
gBCT construct, the expression of gH remained solely within the
cytoplasm of the cell, in a distribution very similar to that seen for
WT gH (Supplemental Fig. 2). These findings support our pre-
ceding experiments investigating T cell recognition of endoge-
nously processed Ag, as addition of the gB C-terminal domain to
the gH protein does not alter its cellular localization or pattern of
Ag presentation.
HLA-DM is expressed in the HLA class II loading compartment,
and we next went on to costain the pattern of glycoprotein ex-
pression with an Ab against HLA-DMa. This revealed that the
vesicular localization of gB-WT coincided directly with HLA-DM
expression and confirms that gB was indeed present within the
HLA class II loading compartment (Fig. 7, top left). Expression of
the gBDCT protein was also retained with HLA-DM in vesicular
structures, although this was less discrete than with the full gB
protein (Fig. 7, bottom left). gH-WT protein and gH-gBCT were
distributed throughout the cell cytoplasm, whereas intense punc-
tate staining of HLA-DM was seen in the perinuclear regions
(Fig. 7, right). No difference was observed between the WT and
gH-gBCT proteins.
Discussion
In this study, we have defined the relative immunodominance of
three of the glycoproteins embedded in the envelope of CMV in
eliciting a T cell response and have related this to their mechanism
of Ag presentation. gB has been the main focus for a CMV vaccine
until recently, but the pentameric complex including gH and gL is
now known to be essential for viral entry into endothelial and
epithelial cells (22). Moreover, most neutralizing Abs are directed
against this complex, which makes it an attractive additional target
for vaccine development. A vaccine that combines gB with gH and
gL might therefore be of great value in relation to inducing both
a neutralizing Ab response and strong T cell immunity. However,
detailed study of the T cell response against the gH and gL pro-
FIGURE 5. Newly identified T cell epitopes are generated during natural infection without the need for de novo synthesis. To determine whether
glycoprotein-derived epitopes are generated in the context of viral infection, HLA-matched fibroblasts, pretreated with IFN-g (A) or autologous PBMCs
(B), were infected with purified CMV for 24 h prior to addition of clonal T cells specific for peptides IRS or QLN, respectively. T cell activation was
detected by analysis of IFN-g in supernatants using ELISA. Shown is a representative of two experiments for each epitope studied.















teins has not been previously performed, even though structural
viral proteins are thought to present good CD4 T cell targets. In
both murine CMV (MCMV) and rhesus CMV (RhCMV) models,
an important role for CD4+ T cells in the control of virus has been
implicated (50, 51), and an inverse correlation was observed be-
tween the degree of virus shedding, the polyfunctionality index,
and proliferative capacities of adult RhCMV-specific CD4+ T cells
(52). The development of an early proliferative CD4 T cell re-
sponse in pregnant women undergoing primary CMV infection has
also been shown to influence the viral transmission rate (12).
Our initial results revealed major differences between the im-
munogenicity of gB in contrast to gH or gL. In particular, a T cell
response against gB was detectable in 95% of all donors, in contrast
to only 20% of individuals in whom T cells specific for gH or gL
could be isolated. This observation is not due simply to the relative
size of the individual proteins. Indeed, at 743 aa, gH is ∼82% the
size of gB, and it is highly abundant within the viral envelope. gL
is certainly smaller than the other two proteins, at 278 aa in length,
but it is equally abundant (53). For gB, the vast majority of these
epitopes were restricted through CD4, but also a small number of
CD8-restricted epitopes were identified, in line with previous
findings. Every gH-specific T cell response identified in the
present study was mediated by CD4+ T cells; however, two CD8-
restricted epitopes have been published previously (35). A T cell
response against gL was rare in our subjects, but it was spread
between CD4- and CD8-restricted epitopes, and as only three
epitopes in the three donors were identified, firm conclusions
about the relative CD4 or CD8 dominance for this protein cannot
be made. This is the first time, to our knowledge, that the T cell
response against gL has been addressed in detail, and the findings
extend observations revealing gB as the most frequently recog-
nized CMV-derived protein, followed by gH and gL (31).
gB is among the most immunodominant of all proteins that have
ever been studied. In 41% of individuals the gB-specific T cell
response comprised .1% of the total CD4+ T cell pool, and
this gB-specific repertoire contains a remarkable breadth of pep-
tide responses that had not been previously observed. Indeed, we
identified 29 peptide epitopes within the protein, of which only 5
have been reported previously (32, 36, 37). In addition to the
breadth of T cell responses, the size of the identified epitope re-
sponses can also be substantial. Apart from the DYS peptide
previously shown to stimulate very strong CD4+ T cell responses,
several other gB-derived epitopes were able to induce strong
CD4+ T cell responses, each representing .0.5% of the total
CD4+ T cell population. Interestingly, although T cell epitopes
were found much less commonly in gH and gL, the magnitude of
these individual responses can also be very substantial. Up to
1.14% of all CD4 T cells were found to be specific for the QLN
peptide from gH, which indicates that the magnitude of CMV-
specific T cell immune responses is not related to the density of
peptide epitopes within the target protein. The mechanism that
underlies this remarkable immunodominance of CMV proteins is
FIGURE 6. gB and gH induce different patterns of T cell recognition. gB-WT protein was truncated after the transmembrane domain (gBDCT), and
correspondingly the C-terminal domain of gB was added to the gH-WT protein (gH-gBCT) to analyze its effect on Ag processing and presentation (A).
Protein expression in HEK293 cells was confirmed by Western blot 24 h following transfection (B). T cell recognition of exogenously (C) or endogenously
(D) processed Ag was determined. All four proteins were processed when taken up exogenously by autologous LCLs and presented to CD4+ T cell clones,
whereas only gB-WT and gBDCTwere processed endogenously for presentation in HLA class II when LCLs were transfected with the target Ag. Graphs in
(C) and (D) summarize three independent experiments for both endogenous and exogenous presentation. Shown are means with SEM.















not well understood, but it may relate to recurrent episodes of
subclinical viral reactivation or initial priming events.
A key finding was also the marked dominance of CD4+ T cell
responses against the two larger glycoproteins in comparison with
much weaker induction of CD8+ T cell responses. CMV-specific
CD4+ T cells have been less well studied, and only a small number
of peptide epitopes have been identified to date. Even so, they play
an important role in control of infection through the direct sup-
pression of viral replication and support of virus-specific CD8+
T cell function and survival (9, 10, 54). In the murine model of
CMV infection, lack of virus-specific CD4+ T cells leads to pro-
longed shedding of the virus from the salivary gland, which is
thought to be one of the main routes of horizontal transmission
(55). A large proportion of virus-specific T cells are indeed lo-
cated within the CD4+ T cell compartment (31), and virus-specific
CD4+ T cells can comprise up to 10% of the peripheral CD4 T
cell compartment (56). CD4+ T cell responses against individual
pathogens are often broader and less focused on particular epi-
topes in comparison with CD8+ responses. Nonetheless, hierar-
chies of immmunodominance can also be discerned in the CD4+
T cell compartment. In the context of viral infection, this has been
analyzed most in-depth for vaccinia virus and EBV (57, 58).
During CMV infection, CD4+ T cell immunity seems to be fo-
cused on structural proteins, such as tegument components and
glycoproteins, which are often expressed late in the virus life
cycle, but abundant in incoming virus particles (31, 59). However,
there are many factors influencing CD4+ T cell immunodomi-
nance in addition to Ag abundance and expression kinetics, in-
cluding HLA restriction element, precursor frequencies of naive
T cells, Ag structure, and competition of Ag at the level of APCs
(60–63). The stability of the HLA class II/peptide complex seems
to play a very important role in determining dominance of indi-
vidual epitopes (64). Owing to the relatively small cohort size in
our study, it is difficult to relate immunodominance of specific
epitopes within individuals according to their HLA genotype.
However it was notable that all seven donors expressing the HLA-
DR*0701 allele displayed a conserved response pattern against
gB. Further studies in larger cohorts will be needed to allow firm
conclusions about immunodominance hierarchies.
Interestingly, we also observed differences in the functional
capacity of T cells in relationship to recognition of the individ-
ual glycoproteins. Most notably, T cells recognizing gB-derived
epitopes displayed a much greater cytotoxic potential with very
strong production of IFN-g, TNF-a, and GzmB. In contrast,
expression of GzmB was substantially reduced in gH- and gL-
specific T cells, although it was noteworthy that these cells
retained the capacity to produce IL-2, indicating that they were
more likely to exert helper function. In terms of polyfunctionality,
gB-specific T cells closely resemble the profile previously ob-
served for T cells specific for pp65 and UL86, which are the other
two most frequently recognized CD4 T cell targets (44, 65). These
observations are also in line with studies from both MCMV and
RhCMV model systems where immunodominant proteins drive a
predominant Th1-type CD4 T cell response, dominated by pro-
duction of IFN-g and TNF-a (59, 66). Studies within HIV in-
fection indicate that polyfunctionality of virus-specific T cells acts
as a surrogate marker for protective immunity (67).
With the purpose of addressing the potential mechanisms that
may underlie the immunodominance of gB, we generated T cell
clones specific for a gB- and a gH-derived epitope from the
same donor. All clones used displayed very similar functional
avidity. In the first instance we could show that both epitopes were
generated in the context of a natural infection in vitro. Rapidly
following infection, within 24 h, T cell activation was detected,
indicating that the incoming virus particles contain sufficient levels
of the glycoprotein to be processed and able to sensitize specific
T cells. This is further supported by the fact that the gB-derived
epitope could be generated from UV-inactivated virus. Both gB
and gH are expressed late in the virus life cycle, but they are
abundant in the envelope of virus particles (53, 68). Evidence
FIGURE 7. gB protein colocalizes with the HLA class II loading compartment, but gH does not. MJS cells were transfected with GFP-expressing
glycoprotein constructs, fixed, and costained with anti–HLA-DM (red). They were then counterstained with DAPI and mounted on microscope slides for
analysis. gB-WT protein was contained exclusively within vesicular structures colocalizing with HLA-DMa (top left). In cells transfected with gH-WT, the
glycoprotein was distributed evenly throughout the cytoplasm, whereas HLA-DM showed punctate staining concentrated particularly in perinuclear regions
(top right). The same pattern was observed for gH-gBCT (bottom right). gBDCT protein expression was observed broadly within the cell cytoplasm but also
retained vesicular localization with relative coexpression with HLA-DM staining (bottom left). Scale bars, 10 mm.















suggests that gB is directed into the endosomal HLA class II
loading compartment, permitting endogenous presentation within
virally infected cells (39). This may provide gB with a crucial
competitive advantage in terms of access to the Ag presentation
pathway compared with other glycoproteins. Having established
T cell clones and the fact that both epitopes are generated in the
context of a viral infection, we went on to study the mechanisms
in more detail. Given that HCMV assembles in endosomal com-
partments, it had been considered probable that proteins such as
gH and gL would also gain access to this mechanism of presen-
tation in virus-infected cells. To address this question, we used the
T cell clones specific for the gB- and gH-derived epitopes to study
presentation of these epitopes following endogenous or exogenous
Ag presentation.
Remarkably, we did not find any evidence for presentation of
endogenous gH, whereas T cells did indeed recognize the gB-
derived epitope when the proteins were expressed endogenously,
confirming its direct access into the HLA class II processing
pathway. Importantly, the gH- and gB-derived epitopes were both
recognized when Ag was processed following exogenous pre-
sentation. To investigate the basis for this difference, we performed
confocal analysis to determine the cellular localization of protein
expression using constructs containing a GFP tag. As previously
reported, gB expression was confined exclusively to vesicular
structures colocalizing with a marker of the HLA class II loading
compartment (HLA-DM). In contrast, gH was dispersed evenly
throughout the cytoplasm, and no costaining with HLA-DM was
observed.
It remains possible that the pattern of glycoprotein expression
may be different in the context of viral infection, as the cytoplasmic
viral assembly compartment is indeed located to the vesicular
structures of infected cells (45, 69). However, budding virus
colocalized with secretory vesicles more so than with late endo-
somes or lysosomes (endocytic vesilcles), suggesting that other
glycoproteins may not be able to enter the HLA class II processing
pathway very efficiently in vivo. This would result in a much more
efficient presentation of gB-derived epitopes in the context of
HLA class II from within virus-infected cells compared with other
structural CMV proteins and therefore may offer an explanation
for the substantially reduced immunodomiance of gH in com-
parison with gB.
The mechanism by which gB gains entry into the endosomal
processing pathway has been proposed to be due to sorting
sequences within the C-terminal domain of the protein (39). We
deleted this domain from gB, in the gBDCT construct, but found,
somewhat to our surprise, that a gB-derived epitope could still be
generated via an endogenous processing route from this protein,
albeit at a slightly reduced level of efficiency. This demonstrates
that the C-terminal domain is not the only mechanism that allows
gB to enter into the endosomal pathway. This observation was
confirmed by analysis of the pattern of cellular expression of the
gBDCT protein. Although this did demonstrate some degree of
cytoplasmic expression, the deletion did not completely abrogate
transport of gB into the HLA class II pathway.
Additionally, transfer of the C-terminal domain onto the gH
protein did not lead to generation of the gH-derived epitope in an
endogenous manner. Indeed, the gH-gBCT protein was not de-
tected in any vesicular structures despite the attachment of the
entire C terminus from gB to its C-terminal region. This indicates
that factors within the gB and gH proteins themselves, possibly
relating to secondary structures embedded within the remaining
protein domains, for example the transmembrane domain (70),
serve to contribute to the pattern of endosomal localization. Ad-
ditionally, other mechanisms may come into play that allow
intracellular generation of CD4+ T cell epitopes in a proteasome-
and TAP-independent manner for presentation in MHC class II
(71, 72). This will however need further investigation.
In summary, our results demonstrate the remarkable T cell
immunodominance of gB in comparison with gH and gL in the
number and range of epitopes contained within the protein and also
differences in the nature of the functional response elicited by
glycoprotein-specific T cells. This most likely reflects the fact that
gB is the only protein that is directed into the endosomal HLA
class II presentation pathway, a process partly, but not completely,
mediated by sequences within the C-terminal domain. These
observations on the unique properties of the gB-specific T cell
response support its role as a core component within a HCMV
vaccine. However, RhCMV and MCMV vaccine models have
demonstrated the increased efficacy of multivalent vaccines, and in
all cases induction of a cellular response correlated with improved
outcome (73, 74). The next generation HCMV vaccines are also
likely to incorporate additional viral proteins, and gH and gL, as
part of the pentameric complex, are leading candidates in this
regard. Our results indicate that future vaccine design strategies
should incorporate approaches that ensure the generation of ade-
quate cellular immunity against these glycoproteins.
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